-
EP3717916
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3717916
| EP3717916 - TARGET INTERFERENCE SUPPRESSED ANTI-DRUG ANTIBODY ASSAY [Right-click to bookmark this link] | Status | No opposition filed within time limit Status updated on 07.11.2025 Database last updated on 28.03.2026 | |
| Former | The patent has been granted Status updated on 29.11.2024 | ||
| Former | Grant of patent is intended Status updated on 18.09.2024 | ||
| Former | Examination is in progress Status updated on 16.07.2021 | ||
| Former | Request for examination was made Status updated on 04.09.2020 | ||
| Former | The international publication has been made Status updated on 07.06.2019 | ||
| Former | unknown Status updated on 01.12.2018 | Most recent event Tooltip | 07.11.2025 | No opposition filed within time limit | published on 10.12.2025 [2025/50] | Applicant(s) | For all designated states F. Hoffmann-La Roche AG Grenzacherstrasse 124 4070 Basel / CH | [2020/41] | Inventor(s) | 01 /
DAHL, Uwe c/o Roche Diagnostics GmbH Nonnenwald 2 82377 Penzberg / DE | 02 /
JORDAN, Gregor c/o Roche Diagnostics GmbH Nonnenwald 2 82377 Penzberg / DE | 03 /
STAACK, Roland c/o Roche Diagnostics GmbH Nonnenwald 2 82377 Penzberg / DE | 04 /
MOHEYSEN-ZADEH, Miriam c/o Roche Diagnostics GmbH Nonnenwald 2 82377 Penzberg / DE | [2020/41] | Representative(s) | Skolaut, Alexander Roche Diagnostics GmbH Patentabteilung LPAA....6164 Nonnenwald 2 82372 Penzberg / DE | [2025/01] |
| Former [2020/41] | Skolaut, Alexander Roche Diagnostics GmbH Patent Department (LPP.....6164) Nonnenwald 2 82372 Penzberg / DE | Application number, filing date | 18804654.4 | 27.11.2018 | [2020/41] | WO2018EP82664 | Priority number, date | EP20170204316 | 29.11.2017 Original published format: EP 17204316 | [2020/41] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2019105916 | Date: | 06.06.2019 | Language: | EN | [2019/23] | Type: | A1 Application with search report | No.: | EP3717916 | Date: | 07.10.2020 | Language: | EN | The application published by WIPO in one of the EPO official languages on 06.06.2019 takes the place of the publication of the European patent application. | [2020/41] | Type: | B1 Patent specification | No.: | EP3717916 | Date: | 01.01.2025 | Language: | EN | [2025/01] | Search report(s) | International search report - published on: | EP | 06.06.2019 | Classification | IPC: | G01N33/68, G01N33/543 | [2020/41] | CPC: |
G01N33/54393 (EP,CN,IL,KR,US);
G01N33/6854 (CN,KR);
G01N33/53 (US);
G01N2400/10 (CN,US)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2020/41]
| Extension states | BA | Not yet paid | ME | Not yet paid | Validation states | KH | Not yet paid | MA | Not yet paid | MD | Not yet paid | TN | Not yet paid | Title | German: | TARGET-INTERFERENZ-UNTERDRÜCKTER ANTI-WIRKSTOFF-ANTIKÖRPERASSAY | [2020/41] | English: | TARGET INTERFERENCE SUPPRESSED ANTI-DRUG ANTIBODY ASSAY | [2020/41] | French: | DOSAGE D'ANTICORPS ANTI-MÉDICAMENT À SUPPRESSION D'INTERFÉRENCES CIBLES | [2024/31] |
| Former [2020/41] | DOSAGE D'ANTICORPS ANTI-MÉDICAMENT À INTERFÉRENCE DE CIBLE SUPPRIMÉE | Entry into regional phase | 29.06.2020 | National basic fee paid | 29.06.2020 | Designation fee(s) paid | 29.06.2020 | Examination fee paid | Examination procedure | 07.05.2020 | Amendment by applicant (claims and/or description) | 29.06.2020 | Examination requested [2020/41] | 29.06.2020 | Date on which the examining division has become responsible | 15.07.2021 | Despatch of a communication from the examining division (Time limit: M04) | 08.10.2021 | Reply to a communication from the examining division | 15.11.2022 | Despatch of a communication from the examining division (Time limit: M06) | 16.05.2023 | Reply to a communication from the examining division | 19.09.2024 | Communication of intention to grant the patent | 23.10.2024 | Fee for grant paid | 23.10.2024 | Fee for publishing/printing paid | 23.10.2024 | Receipt of the translation of the claim(s) | Divisional application(s) | EP24221977.2 / EP4528277 | Opposition(s) | 02.10.2025 | No opposition filed within time limit [2025/50] | Fees paid | Renewal fee | 10.11.2020 | Renewal fee patent year 03 | 08.11.2021 | Renewal fee patent year 04 | 10.11.2022 | Renewal fee patent year 05 | 22.11.2023 | Renewal fee patent year 06 | 21.11.2024 | Renewal fee patent year 07 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | CZ | 01.01.2025 | HR | 01.01.2025 | SK | 01.01.2025 | SM | 01.01.2025 | NO | 01.04.2025 | IS | 01.05.2025 | [2025/49] |
| Former [2025/46] | CZ | 01.01.2025 | |
| HR | 01.01.2025 | ||
| SM | 01.01.2025 | ||
| NO | 01.04.2025 | ||
| IS | 01.05.2025 | ||
| Former [2025/36] | CZ | 01.01.2025 | |
| HR | 01.01.2025 | ||
| NO | 01.04.2025 | ||
| IS | 01.05.2025 | ||
| Former [2025/34] | HR | 01.01.2025 | |
| NO | 01.04.2025 | ||
| IS | 01.05.2025 | Cited in | International search | [I] WO2008031532 (HOFFMANN LA ROCHE et al.) | [I] WO2015123315 (GENZYME CORP et al.) | [ID] MOXNESS M ET AL: "Immunogenicity Testing by Electrochemiluminescent Detection for Antibodies Directed against Therapeutic Human Monoclonal Antibodies", CLINICAL CHEMISTRY, vol. 51, no. 10, 1 September 2005 (2005-09-01), AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY, WASHINGTON, DC, pages 1983 - 1985, XP003019464, ISSN: 0009-9147, DOI: 10.1373/CLINCHEM.2005.053272 DOI: http://dx.doi.org/10.1373/clinchem.2005.053272 | [ID] PATTON A ET AL: "An acid dissociation bridging ELISA for detection of antibodies directed against therapeutic proteins in the presence of antigen", JOURNAL OF IMMUNOLOGICAL METHODS, vol. 304, no. 1-2, 1 September 2005 (2005-09-01), ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, pages 189 - 195, XP027659212, ISSN: 0022-1759, [retrieved on 20050901], DOI: 10.1016/j.jim.2005.06.014 DOI: http://dx.doi.org/10.1016/j.jim.2005.06.014 | [ID] ZOGHBI JAD ET AL: "A breakthrough novel method to resolve the drug and target interference problem in immunogenicity assays", JOURNAL OF IMMUNOLOGICAL METHODS, vol. 426, November 2015 (2015-11-01), pages 62 - 69, XP002785311, DOI: 10.1016/j.jim.2015.08.002. DOI: http://dx.doi.org/10.1016/j.jim.2015.08.002 | [I] LLINARES-TELLO F. ET AL.,: "THU0166 Usefullness of the acid dissociation in immunogenicity detection in patients in treatment with anti-TNF drugs", BMJ, vol. 73, no. suppl, 2, 11 June 2014 (2014-06-11), XP002785312 DOI: http://dx.doi.org/10.1136/annrheumdis-2014-eular.3700 | [I] UWE WESSELS ET AL: "Detection of antidrug antibodies against human therapeutic antibodies lacking Fc-effector functions by usage of soluble Fc[gamma] receptor I", BIOANALYSIS, vol. 8, no. 20, 1 October 2016 (2016-10-01), London, UK, pages 2135 - 2145, XP055538060, ISSN: 1757-6180, DOI: 10.4155/bio-2016-0182 DOI: http://dx.doi.org/10.4155/bio-2016-0182 | by applicant | WO2008031532 | WO2015123315 | WO2009080251 | WO2009080252 | WO2009080253 | WO2009080254 | WO2010112193 | WO2010115589 | WO2010136172 | WO2010145792 | WO2010145793 | EP0580979 | WO9005301 | WO9011511 | WO9214138 | EP0061888 | US2016167054 | US6355245 | US7432356 | WO2005065607 | WO2007096586 | WO2008060790 | WO2010054403 | WO0230886 | WO2004006653 | WO2010015608 | MOXNESS, M. ET AL., ANN. N. Y. ACAD. SCI. USA, vol. 1005, 2003, pages 265 - 268 | PATTON, A. ET AL., J. IMMUNOL. METH., vol. 304, 2005, pages 189 - 195 | LEE, J.W. ET AL., AAPS J., vol. 13, 2011, pages 99 - 110 | KELLY, M. ET AL., AAPS J., vol. 15, 2013, pages 646 - 658 | DAVIS, R.A. ET AL., J. PHARM. BIOMED. ANAL., vol. 48, 2008, pages 897 - 901 | SALIMI-MOOSAVI, H. ET AL., J. PHARM. BIOMED. ANAL., vol. 51, 2010, pages 1128 - 1133 | SMITH, H.W. ET AL., REGUL. TOXICOL. PHARMACOL., vol. 49, 2007, pages 230 - 237 | BOURDAGE, J.S. ET AL., J. IMMUNOL. METH., vol. 327, 2007, pages 10 - 17 | ZOGHBI, J. ET AL., J. IMMUNOL. METH., vol. 426, 2015, pages 62 - 69 | COLLET-BROSE, J. ET AL., J. IMMUNOL. RES., 2016 | HAGE, D.S., ANAL. CHEM., vol. 71, 1999, pages 294R - 304R | LU, B. ET AL., ANALYST, vol. 121, 1996, pages 29R - 32R | WILCHEK, M.; BAYER, E.A., METHODS ENZYMOL., vol. 184, 1990, pages 467 - 469 | ASLAM M.; DENT, A.: "Bioconjugation", 1999, MACMILLAN REF. LTD., pages: 50 - 100 | MARTIN, C.R. ET AL., ANALYTICAL CHEMISTRY-NEWS & FEATURES, vol. 70, 1998, pages 322A - 327A | BUTLER, J.E., METHODS, vol. 22, 2000, pages 4 - 23 | MOXNESS, M. ET AL., CLIN. CHEM., vol. 51, no. 10, pages 1983 | PATTON, A. ET AL., J. IMMUNOL. METHODS, vol. 304, 2005, pages 189 | HOLERS ET AL., IMMUNOL. REV., vol. 223, 2008, pages 300 - 316 | DMYTRIJUK ET AL., THE ONCOLOGIST, vol. 13, 2008, pages 894 - 910 |